GeloMyrtol (ELOM-080) / Nadurel Pharma - LARVOL DELTA

Randomised, Placebo-Controlled, Double-Blind Trial to Assess Efficacy and Safety of ELOM-080 in Outpatients with COVID-19. (PubMed, Adv Ther) - P2 | "We have shown that patients with dysfunctional MCC benefit from treatment with ELOM-080. These results might be of clinical importance, as up to now no therapy has obtained market approval for the treatment of outpatients with COVID-19."

Journal • Cough • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phytomedicine ELOM-080 in Acute Viral Rhinosinusitis: A Randomized, Placebo-Controlled, Blinded Clinical Trial. (PubMed, Laryngoscope) - "ELOM-080 improves the burden of AVRS significantly in comparison to placebo, remission of symptoms occurred 3 days earlier. The results confirm the efficacy and safety of ELOM-080 for treatment of AVRS."

Journal • Inflammation • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis

Food Interactions Observed in a Pharmacokinetic Investigation Comparing Two Marketed Cold Preparations (BNO1016 and ELOM-080) after Administration to Beagle Dogs - A Pilot Study. (PubMed, Planta Med) - "Furthermore, lag times of some analytes, up to 3 - 4 h, and corresponding time to reach maximum concentration values, up to 6 - 8 h, occurred. In contrast to BNO 1016, these findings suggest that, as with other enteric-coated formulations, there may also be a significant risk for food effects with ELOM-080 in humans."

Journal • PK/PD data

Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial. (PubMed, Adv Ther) - P2 | "These exploratory data suggest the potential for ELOM-080 to improve respiratory status during and after hospitalisation in patients with COVID-19."

Journal • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Celecoxib and Myrtol: A Novel Therapy for Recurrent Appendiceal Mucinous Neoplasms With Extensive Peritoneal Dissemination. (PubMed, Am J Clin Oncol) - "Our feasibility study suggests that a regimen of Celecoxib-Myrtol is well tolerated and may prolong PFS and OS in patients with recurrent AMNs with peritoneal spread."

Journal • Appendix Cancer • Oncology • Peritoneal Cancer • CEACAM5

Start of clinical trial with GeloMyrtol in COVID-19 patients (Canada Newswire) - "Nadurel Pharma is proud to announce that the German pharmaceutical company Pohl-Boskamp received the final approval to conduct its COVARI study December 16, meaning that patients can now be enrolled. This study will evaluate ELOM-080, the active substance of the respiratory tract drug GeloMyrtol®, as an additional component in the therapy for COVID-19 patients. The results of the study may also be highly relevant for treating patients at home....The pharmaceutical company Pohl-Boskamp is now starting a multicenter, placebo-controlled study in Germany, in which several university hospitals will take part."

Trial status • Infectious Disease • Novel Coronavirus Disease

A clinical trial to assess the efficacy and safety of PB432 in COVID-19 positive inpatients with acute respiratory problems (clinicaltrialsregister.eu) - P2; N=150; Ongoing; Sponsor: G. Pohl-Boskamp GmbH & Co. KG

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases